MedTrace Logo

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

NCT00073008 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2017-02-28

Study results available
· View outcomes & findings →

Summary

This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.

Conditions

  • Lung Cancer, Non-Small Cell

Interventions

DRUG

GW572016 (lapatinib)

tyrosine kinase inhibitor

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00073008 on ClinicalTrials.gov